Journal
SURGICAL INNOVATION
Volume 16, Issue 4, Pages 324-329Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1553350609353609
Keywords
biologic mesh; abdominal wall reconstruction; hernia repair; infection; cross-linking
Categories
Ask authors/readers for more resources
Background. There is limited research for xenograft biologic mesh performance in the setting of infection despite widespread use and significant associated costs. Design. The authors retrospectively reviewed an FDA database for reported xenograft adverse events (AEs). All meshes were used in the setting of abdominal wall reconstruction from 1997 to 2008. Results. The authors identified 150 AEs. Permacol and Collamend comprised 75% (n = 112) of reported cases. Main AEs included acute mechanical failure (42%; n = 63), mesh disintegration (32%; n = 48), and poor mesh integration (13%; n = 20); 80% of cases were described as infected, and nearly 90% of AEs required reoperation. Conclusions. Major complications are reported to the FDA for xenograft biologic meshes. Cross-linked meshes had the most AE reports to the FDA. The intrinsic properties of meshes and how they relate to infection-related outcomes are poorly understood. The findings from this FDA database review point toward a need to carefully evaluate these products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available